Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | BCL6 | P41182 | 2/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.36 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 2/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972903 | 1.00 | KCNQ3 (0.41) | KCNQ3KCNQ2HTTALDH1A1GAA | |
| SCHEMBL1827513 | 0.80 | ALDH1A1 (0.39) | HTTALDH1A1GAAKDM4ESMN1; SMN2 | |
| SCHEMBL23912507 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KDM4ESMN1; SMN2NPC1POLB | |
| SCHEMBL21045724 | 0.80 | KCNQ3 (0.44) | KCNQ3KCNQ2HTTALDH1A1KDM4E | |
| SCHEMBL30503613 | 0.78 | NPC1 (0.43) | ALDH1A1GAAKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL1424930 | 0.78 | NPC1 (0.43) | ALDH1A1GAAKDM4ESMN1; SMN2NPC1 | |
| SCHEMBL20521515 | 0.78 | KDM1A (0.46) | HTTKDM1APDGFRBPDGFRAPDE10A | |
| SCHEMBL1425419 | 0.77 | S1PR1 (0.42) | KCNQ3KCNQ2HTTALDH1A1KDM4E | |
| SCHEMBL2610403 | 0.77 | SLC6A4 (0.41) | HTTALDH1A1PDGFRBPDGFRAPDE10A | |
| SCHEMBL8118182 | 0.77 | DRD1 (0.39) | HTTALDH1A1KDM4EPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2026-05-07 | — | — | US | disclosed |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | AMGEN INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12156874-B2 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2024-12-03 | — | — | US | disclosed |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2024-09-26 | — | — | US | disclosed |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2024-04-23 | — | — | US | disclosed |
| CN-113677673-B | Inhibitors of TRPC6 | 勃林格殷格翰国际有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-01-04 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| US-RE49699-E1 | Inhibitors of TRPC6 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-17 | — | — | US | disclosed |
| EP-2694521-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck Sharp & Dohme Corp. (US) | 2014-02-12 | — | — | EP | disclosed |
| US-20140023667-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | Merck, Sharp & Dohme Corp. (US) | 2014-01-23 | — | — | US | disclosed |
| EP-2626350-A1 | CYCLOPROPANE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012138590-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-8268848-B2 | Cyclopropane compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125364-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | HTR6, HTR3C, OPRD1 | KCNQ3 1475/4885KCNQ2 2107/4885HTT 96/4885 |
| US-20240002397-A1 | 3-AMINO PYRROLIDINE AND PIPERIDINE MACROCYCLIC OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, OXTR | KCNQ3 1136/4885KCNQ2 1676/4885HTT 150/4885 |
| US-11964961-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | DRD2, DRD1, HTR1D | KCNQ3 1258/4885KCNQ2 1588/4885HTT 33/4885 |
| US-20120095031-A1 | CYCLOPROPANE COMPOUND | HCRTR1, HCRTR2, CNR1 | KCNQ3 977/4885KCNQ2 964/4885HTT 939/4885 |
| US-20240317713-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, HTR1D | KCNQ3 1258/4885KCNQ2 1588/4885HTT 33/4885 |
| US-12473289-B2 | Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use | SCD5, SCD, FADS2 | KCNQ3 2776/4885KCNQ2 2402/4885HTT 4351/4885 |
| US-20140023667-A1 | PYRROLIDINE-FUSED THIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE | BACE1, PSEN1, BACE2 | KCNQ3 4573/4885KCNQ2 4160/4885HTT 224/4885 |
| US-12156874-B2 | Inhibitors of TRPC6 | TRPC6, TRPC1, TRPC3 | KCNQ3 455/4885KCNQ2 506/4885HTT 3341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.